Hematology Updates
All the atest articles, research and news from worlds leading Haematology Journals. Discussion group https://t.me/Professional_Medical_Discussion
- 24 hours
- +3
- 7 days
- –
- 30 days
- +123
- Reactions
- 0
- Reposts
- –
- Comments
- –
Subscriber growth
Hematology Updates has 7,092 subscribers. It gained 123 subscribers in the last 30 days (1.8%).
Daily numbers, last 30 days
| Date | Subscribers | Change | Posts | Avg. post views |
|---|---|---|---|---|
| 11 Nov | 7,092 | +3 | 1 | 112 |
| 10 Nov | 7,089 | +6 | 0 | – |
| 9 Nov | 7,083 | 0 | 1 | 277 |
| 8 Nov | 7,083 | +4 | 0 | – |
| 6 Nov | 7,079 | +110 | 0 | – |
| 6 Oct | 6,969 | – | 0 | – |
Views as a post ages
Average views at each age, posts of the last 30 days.
- 7 days
- 373
When it posts
Times in UTC. 22 posts in 90 days.
Recent posts
-
Mediator kinase inhibition exposes a transcriptional vulnerability and synergizes with venetoclax in AML https://www.nature.com/articles/s41375-026-03173-0
112 views -
Mesenchymal stromal cells drive immune escape in MDS and sAML through metabolic rewiring of NK cells https://www.nature.com/articles/s41375-026-03172-1
277 views -
Hyperactivation of type I IFN signaling underlies a broad inflammatory program in VEXAS syndrome https://www.nature.com/articles/s41375-026-03186-9
469 views -
Maternal donor risk in haploidentical transplant with post-transplant cyclophosphamide: the role of recipient sex https://www.nature.com/articles/s41375-026-03179-8
404 views 2 Reactions -
Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia https://www.nature.com/articles/s41375-026-03184-x
478 views -
Salvage therapy for immune-mediated bone marrow failure https://www.nature.com/articles/s41375-026-03180-1
403 views -
Mutant calreticulin-driven myeloproliferative neoplasms favour the emergence of TIGIT-positive NK cells https://www.nature.com/articles/s41375-026-03175-y
337 views -
The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma https://www.nature.com/articles/s41375-026-03174-z
393 views -
Clinical and molecular characteristics of <i>FLT3</i>-ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy https://www.nature.com/articles/s41375-026-03165-0
490 views -
[Articles] Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00246-2/fulltext?rss=yes
445 views
-
Clinical and molecular characteristics of <i>FLT3</i>-ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy https://www.nature.com/articles/s41375-026-03165-0
490 views -
Relcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia https://www.nature.com/articles/s41375-026-03184-x
478 views -
Hyperactivation of type I IFN signaling underlies a broad inflammatory program in VEXAS syndrome https://www.nature.com/articles/s41375-026-03186-9
469 views -
[Articles] Incidence of clinically diagnosed infections in children with sickle cell anaemia treated with oral hydroxyurea in Angola, DR Congo, Kenya, and Uganda: a retrospective cohort study from the REACH trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00246-2/fulltext?rss=yes
445 views -
Maternal donor risk in haploidentical transplant with post-transplant cyclophosphamide: the role of recipient sex https://www.nature.com/articles/s41375-026-03179-8
404 views 2 Reactions -
Salvage therapy for immune-mediated bone marrow failure https://www.nature.com/articles/s41375-026-03180-1
403 views -
[Comment] Hydroxyurea benefits for sickle cell anaemia in sub-Saharan Africa https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00261-9/fulltext?rss=yes
402 views -
The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma https://www.nature.com/articles/s41375-026-03174-z
393 views -
[Articles] MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00228-0/fulltext?rss=yes
339 views -
Mutant calreticulin-driven myeloproliferative neoplasms favour the emergence of TIGIT-positive NK cells https://www.nature.com/articles/s41375-026-03175-y
337 views
Questions about Hematology Updates
How many subscribers does Hematology Updates have?
Hematology Updates (@haematology_updates) has 7,092 subscribers as of November 12, 2026.
Is Hematology Updates growing?
Yes. It gained 123 subscribers in the last 30 days (1.8%).
What is Hematology Updates about?
It is listed in Health, and posts mostly in English. The channel describes itself as: “All the atest articles, research and news from worlds leading Haematology Journals. Discussion group https://t.me/Professional_Medical_Discussion”
Where does Hematology Updates rank?
By subscribers it is #140 in Health, #2,611 among English channels, #3,058 worldwide.
Does Hematology Updates post ads?
None of its 22 posts in the last 30 days carried an ad label such as #ad or Sponsored. Unlabelled promotions can’t be detected.
When does Hematology Updates post?
Most often on Friday, around 01:00 UTC. It publishes about 2 posts a day.
Statistics updated 5 minutes ago.